- Hemophilia, a rare genetic bleeding disorder characterized by a deficiency in clotting factors, continues to be a critical focus area within the global rare disease and specialty therapeutics sectors due to its lifelong management needs and evolving treatment landscape
- The escalating demand for hemophilia treatments is primarily fueled by improved disease awareness, enhanced diagnostic capabilities, and the increasing adoption of long-acting recombinant factors and emerging gene therapies aimed at reducing bleeding episodes and treatment burden
- North America dominated the hemophilia market with the largest revenue share of 46.3% in 2024, driven by advanced healthcare infrastructure, early access to novel therapies, and supportive reimbursement policies, with the U.S. leading in clinical trials and the adoption of cutting-edge gene therapies and extended half-life products
- Asia-Pacific is expected to be the fastest growing region in the hemophilia market during the forecast period due to increasing healthcare investments, rising diagnosis rates, and expanding access to specialty care
- Hemophilia A segment dominated the global hemophilia market with a market share of 60.9% in 2024, attributed to its higher prevalence compared to other types and the availability of a broad range of treatment options including FVIII concentrates and prophylactic regimens
